FDA Opens Its Review Files to Foreign Regulators, Starting With PEPFAR Drugs
The FDA unveiled the Global Reliance Disclosure Program on 17 November 2026, letting drug sponsors request minimally redacted approval packages and hand them to regulators abroad. The program kicked off 30 October 2026 with a PEPFAR tentative approval for HIV drug lenacapavir, and widens to all novel drugs and biologics in January 2027.
- Original source: casrai.org.
- The source published it on Nov 17, 2026 at 8:01 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Sponsors can now ask the FDA for its approval packages with only minimal non-public information stripped out, then pass them to a foreign regulatory authority weighing its own marketing application. The packages carry the agency's detailed scientific review and its regulatory rationale. According to the FDA, a foreign regulator can lean on that science-based review rather than repeating a full evaluation from scratch, while still owning its final decision.
The Global Reliance Disclosure Program didn't start with a splashy launch. It began on 30 October 2026 with a PEPFAR tentative approval for lenacapavir, an HIV prevention and treatment drug. FDA Deputy Commissioner Grace Graham called the agency the global gold standard, and Mark Abdoo, FDA's Associate Commissioner for Global Policy and Strategy, said the agency's leadership works best when it's collaborative.
There's a hard edge to the program. The GRDP is a route to a foreign regulator, not a public dump of review documents — anyone chasing the records for academic analysis of a review still has to use the existing FOIA disclosure route. Until the expansion, only certain PEPFAR tentative approvals qualify, and tentatively approved ANDA products stay outside the door. FDA says eligible applicants will learn how to take part in their approval letters.
The scope grows early next year. FDA plans to widen the program in January 2027 to all novel drugs and biologics — NME NDAs and 351(a) BLAs — and to add a request pathway for products already on the market in early 2027.
Regulatory reliance isn't new. The World Health Organization published its Good Reliance Practices guidance on 29 April 2021 to make regulation more efficient and speed access to quality-assured, effective and safe medical products, covering medicines, vaccines, blood and blood products, and medical devices including in vitro diagnostics. That guidance draws on Pan American Health Organization recommendations and a 2018 to 2019 survey of regulators. The GRDP supplies the actual document that makes reliance workable: a foreign regulator needs the FDA review itself.
Reactions rolled in fast. The law-firm bulletin Ermer Suter's Tuesday Report of 17 November 2026 called the GRDP a landmark initiative that may accelerate patient access to innovative therapies worldwide. Korean outlet Medipana reported on 18 November 2026 that FDA expects the program to cut duplicative reviews and narrow the gap between US and overseas approval dates, with the biggest lift for countries short on review staff and capacity. Medipana also noted Korea's Ministry of Food and Drug Safety will decide how it uses the materials based on its own systems and procedures — FDA didn't name Korea as a participant. Separately, a 2 November 2026 Unitaid report on FDA's tentative approval of a first generic injectable lenacapavir for HIV prevention, made by Dr. Reddy's Laboratories, said the move could support national approvals and speed introduction across the 120 low- and middle-income countries covered by Gilead's voluntary licensing program; that report doesn't mention the GRDP, tying the two only by subject.
TopicsFDA · Grace Graham · Mark Abdoo · lenacapavir · Dr. Reddy's Laboratories · Gilead Sciences · World Health Organization · PEPFAR
Source: casrai.org
Written by AI from verified reporting.
More stories
- Health & science theguardian.com Caught by @Crypto fresh 1 viewViagra-Style Pill Slows Alzheimer's Decline by 31% in Global Trial
- Health & science theguardian.com 1 viewNHS staff snooped on patients' records 3,029 times in five years
- Health & science medicalxpress.com 1 viewFDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes
- Health & science medicalxpress.com 1 viewFDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

